Sage Therapeutics Inc. (SAGE)
Symbol Info
Listed Symbol SAGE
Name Sage Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $90,273,000
Latest Fiscal EPS $-8.07
Price Info
21 Day Moving Average $163.1429
21 Day EMA $162.850650
50 Day Moving Average $166.9954
50 Day EMA $165.768590
200 Day EMA $160.005870
200 Day Moving Average 155.555650
52 Week High $193.56
52 Week Low $79.88
52 Week Change $12.438800
Alpha 0.027062
Beta 2.5524
Standard Deviation 0.204811
R2 0.184115
Periods 60
Share Information
10 Day Average Volume 367,730
20 Day Average Volume 378,702
30 Day Average Volume 354,514
50 Day Average Volume 376,304
Outstanding Shares 51,656,993
Float Shares 50,809,662
Percent Float 98.36%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 583
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 6,907,007
Institute Holdings Percent -
Institute Sold Previous 3 Months 4,703,309
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 847,331
Price Change
7 Day Price Change $5.5400085
7 Day Percent Change 3.47%
21 Day Price Change $-6.3399963
21 Day Percent Change -3.69%
30 Day Price Change $0.6500092
30 Day Percent Change 0.39%
Month To Date Price Change $-6.34
Month To Date Percent -3.69%
90 Day Price Change $-15.770004
90 Day Percent Change -8.71%
Quarter To Date $-17.759995
Quarter To Date Percent -9.70%
180 Day Price Change $12.869995
180 Day Percent Change 8.44%
200 Day Price Change $9.750000
200 Day Percent Change 6.27%
Year To Date $69.540000
Year To Date Percent 72.60%
Profile
Description Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.
Details
Issue Type CS
Market Cap $8,540,450,653
Sec Type EQS
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 51,656,993
CEO Jeffrey M. Jonas
Employees 637
Last Audit UQ
Classification
CIK 0001597553
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 215 First Street
Cambridge, MA 2142
Website http://www.sagerx.com
Facisimile +1 617 299-8379
Telephone +1 617 299-8380
Email paul.cox@sagerx.com
Key Ratios
Profitability
EBIT Margin -39,682.2
EBITDA Margin -39,584.8
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin 95.00
Profit Margin TOT -
Income Statements
Revenue $1,611,000
Revenue Per Share $0.0312
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $7,476,684,533
Price To Sales 5,301.335000
Price To Free Cash -18.4
PE High Last 5 Years -
Price To Book 7.2
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 7.2
Financial Strength
Total Debt To Equity 0.0
Int Coverage -
Current Ratio 16.0
Leverage Ratio 1.1
Quick Ratio 15.7
Long Term Debt To Capital 0.03
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -50.73
Return On Equity -54.4
Return On Capital -52.23
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
SAGE
Sage Thera..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.